BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Cho H, Park YS, Kang WK, Kim J, Lee S. Thymidylate Synthase (TYMS) and Dihydropyrimidine Dehydrogenase (DPYD) Polymorphisms in the Korean Population for Prediction of 5-Fluorouracil-Associated Toxicity. Therapeutic Drug Monitoring 2007;29:190-6. [DOI: 10.1097/ftd.0b013e318040b1fe] [Cited by in Crossref: 33] [Cited by in F6Publishing: 9] [Article Influence: 2.2] [Reference Citation Analysis]
Number Citing Articles
1 Gotanda K, Hirota T, Matsumoto N, Ieiri I. MicroRNA-433 negatively regulates the expression of thymidylate synthase (TYMS) responsible for 5-fluorouracil sensitivity in HeLa cells. BMC Cancer 2013;13:369. [PMID: 23915286 DOI: 10.1186/1471-2407-13-369] [Cited by in Crossref: 36] [Cited by in F6Publishing: 36] [Article Influence: 4.0] [Reference Citation Analysis]
2 Fariña-Sarasqueta A, Gosens MJ, Moerland E, van Lijnschoten I, Lemmens VE, Slooter GD, Rutten HJ, van den Brule AJ. TS gene polymorphisms are not good markers of response to 5-FU therapy in stage III colon cancer patients. Cell Oncol (Dordr) 2011;34:327-35. [PMID: 21630057 DOI: 10.1007/s13402-011-0030-z] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
3 Cinausero M, Aprile G, Ermacora P, Basile D, Vitale MG, Fanotto V, Parisi G, Calvetti L, Sonis ST. New Frontiers in the Pathobiology and Treatment of Cancer Regimen-Related Mucosal Injury. Front Pharmacol 2017;8:354. [PMID: 28642709 DOI: 10.3389/fphar.2017.00354] [Cited by in Crossref: 73] [Cited by in F6Publishing: 68] [Article Influence: 14.6] [Reference Citation Analysis]
4 Offer SM, Fossum CC, Wegner NJ, Stuflesser AJ, Butterfield GL, Diasio RB. Comparative functional analysis of DPYD variants of potential clinical relevance to dihydropyrimidine dehydrogenase activity. Cancer Res. 2014;74:2545-2554. [PMID: 24648345 DOI: 10.1158/0008-5472.can-13-2482] [Cited by in Crossref: 94] [Cited by in F6Publishing: 40] [Article Influence: 11.8] [Reference Citation Analysis]
5 Al-Khateeb M, Awidi A, Al-Hadidi K, Battah A. Low Incidence of the DPD IVS14+1G>A Polymorphism in Jordanian Breast and Colorectal Cancer patients. Asian Pac J Cancer Prev 2017;18:1651-4. [PMID: 28670884 DOI: 10.22034/APJCP.2017.18.6.1651] [Reference Citation Analysis]
6 Basile D, Di Nardo P, Corvaja C, Garattini SK, Pelizzari G, Lisanti C, Bortot L, Da Ros L, Bartoletti M, Borghi M, Gerratana L, Lombardi D, Puglisi F. Mucosal Injury during Anti-Cancer Treatment: From Pathobiology to Bedside. Cancers (Basel) 2019;11:E857. [PMID: 31226812 DOI: 10.3390/cancers11060857] [Cited by in Crossref: 29] [Cited by in F6Publishing: 26] [Article Influence: 9.7] [Reference Citation Analysis]
7 van Kuilenburg AB, Meijer J, Mul AN, Meinsma R, Schmid V, Dobritzsch D, Hennekam RC, Mannens MM, Kiechle M, Etienne-Grimaldi MC. Intragenic deletions and a deep intronic mutation affecting pre-mRNA splicing in the dihydropyrimidine dehydrogenase gene as novel mechanisms causing 5-fluorouracil toxicity. Hum Genet. 2010;128:529-538. [PMID: 20803296 DOI: 10.1007/s00439-010-0879-3] [Cited by in Crossref: 78] [Cited by in F6Publishing: 68] [Article Influence: 6.5] [Reference Citation Analysis]
8 Shin JG, Cheong HS, Kim JY, Kim LH, Han CS, Kim JO, Kim HD, Kim YH, Chung MW, Han SY, Shin HD. Screening of dihydropyrimidine dehydrogenase genetic variants by direct sequencing in different ethnic groups. J Korean Med Sci 2013;28:1129-33. [PMID: 23960437 DOI: 10.3346/jkms.2013.28.8.1129] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
9 Leung HW, Chan AL. Association and prediction of severe 5-fluorouracil toxicity with dihydropyrimidine dehydrogenase gene polymorphisms: A meta-analysis. Biomed Rep 2015;3:879-83. [PMID: 26623034 DOI: 10.3892/br.2015.513] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
10 Chahla E, Cheesman A, Hammami M, Taylor JR, Poddar N, Garrett RW, Alkaade S. A unique case of a patient with rectal cancer who developed benign esophageal stenosis after localized rectal radiation and systemic chemotherapy. Case Rep Gastroenterol 2015;9:44-8. [PMID: 25802497 DOI: 10.1159/000376608] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]